3 ms·
I dunno. It's been well known for a while that the first vaccines are likely to have substantially less than 90% effectiveness, but most leaders are still point
by SpicyLemonZest 6y ago
I dunno. It's been well known for a while that the first vaccines are likely to have substantially less than 90% effectiveness, but most leaders are still pointing to a widely distributed vaccine as the end of panic mode.
- salmon30salmon 6y agoCould you cite this assertion? The data that I've reviewed shows a pretty robust immune response, especially given a booster within 1 month. This is specifically for the mRNA vaccines by Pfizer and Moderna. Please also remember, when speaking of the United States, around 15% of the population has already been infected by SARS-COV-2[1], and even the most pessimistic of epidemiologists say that herd immunity is around 60%. So we need "infect" 45% more of the population to give COVID-19 a knockout blow. even 50% efficacy (which I believe is the standard lower bound for an approved vaccine), 300 million doses should do quite nicely (600 if you count boosters, which I should have). Those are all worst case scenarios. Most likely, the efficacy will be higher than 50% (maybe not 90%, but I think 75% is safe) and most likely herd immunity is below 60% (due to heterogeneity in mixing and t-cell "immunity"). Things are looking up! [1] https://covid19-projections.com/us https://covid19-projections.com/us
- lsllc 6y agoThe BBC had an interesting article on the "hidden protection from COVID19" from T-cell "immunity": https://www.bbc.com/future/article/20200716-the-people-with-hidden-protection-from-covid-19 https://www.bbc.com/future/article/20200716-the-people-with-... The article references this paper: https://www.cell.com/cell/pdf/S0092-8674(20)30610-3.pdf https://www.cell.com/cell/pdf/S0092-8674(20)30610-3.pdf "Importantly, we detected SARS-CoV-2-reactive CD4+ T cells in 40%–60% of unexposed individuals, suggesting cross-reactive T cell recognition between circulating ‘‘common cold’’ coronaviruses and SARS-CoV-2."